The Biostatistics Shared Resource exists to provide statistical support to investigators of the SJCRH Cancer Center for peer-reviewed, funded grants and statistical design for institutional clinical and pre-clinical studies as well as for basic science projects. The primary objectives of the Biostatistics Shared Resource are to provide Cancer Center investigators access to uniformly high quality, innovative statistical science; a centralized randomization system; access to statistical software; technical support for a web-based distributed data management system; and advice on data management issues. Traditionally and importantly the Biostatistics Shared Resource resides in the Department of Biostatistics. By supporting this resource as a component of an academic department, the NCI ensures that biostatisticians are provided the autonomy and freedom to apply their expertise as dictated by statistical science. Benefits to the Cancer Center include clinical protocols and publications based on statistically sound study designs, statistically appropriate analyses and statistically valid inferences. The CCSG provides critical funding that is necessary to ensure centralization of function and stability of support permitting the benefits to be accomplished in a timely, cost effective manner. The Department of Biostatistics includes nine faculty (three are being recruited), one adjunct clinical faculty member, three post-doctoral fellows, 12 masters level biostatisticians (two are being recruited), three statistical graduate students, three computer scientists, one assistant director (OBC for the PBTC), one protocol coordinator (PBTC), one fiscal coordinator and two administrative assistants. Although most staff members in the department provide support to investigators in the Cancer Center, our application requests partial funding for only a subset of individuals with major commitments to the Cancer Center and organized into the Biostatistics Shared Resource.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA021765-25S1
Application #
6602680
Study Section
Project Start
2002-06-24
Project End
2007-02-28
Budget Start
Budget End
Support Year
25
Fiscal Year
2002
Total Cost
Indirect Cost
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Bjornard, Kari L; Gilchrist, Laura S; Inaba, Hiroto et al. (2018) Peripheral neuropathy in children and adolescents treated for cancer. Lancet Child Adolesc Health 2:744-754
Gibson, Todd M; Li, Chenghong; Armstrong, Gregory T et al. (2018) Perceptions of future health and cancer risk in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. Cancer 124:3436-3444
Yang, Kai; Blanco, Daniel Bastardo; Chen, Xiang et al. (2018) Metabolic signaling directs the reciprocal lineage decisions of ?? and ?? T cells. Sci Immunol 3:
Ferrolino, Mylene C; Mitrea, Diana M; Michael, J Robert et al. (2018) Compositional adaptability in NPM1-SURF6 scaffolding networks enabled by dynamic switching of phase separation mechanisms. Nat Commun 9:5064
Rusch, Michael; Nakitandwe, Joy; Shurtleff, Sheila et al. (2018) Clinical cancer genomic profiling by three-platform sequencing of whole genome, whole exome and transcriptome. Nat Commun 9:3962
Luo, Yi; Shao, Lijian; Chang, Jianhui et al. (2018) M1 and M2 macrophages differentially regulate hematopoietic stem cell self-renewal and ex vivo expansion. Blood Adv 2:859-870
Peterson, Rachel K; Ashford, Jason M; Scott, Sarah M et al. (2018) Predicting parental distress among children newly diagnosed with craniopharyngioma. Pediatr Blood Cancer 65:e27287
Kumar, Rahul; Liu, Anthony P Y; Orr, Brent A et al. (2018) Advances in the classification of pediatric brain tumors through DNA methylation profiling: From research tool to frontline diagnostic. Cancer 124:4168-4180
Dove, Austin P; Manole, Bogdan-Alexandru; Wakefield, Daniel V et al. (2018) Managing local-regional failure in children with high-risk neuroblastoma: A single institution experience. Pediatr Blood Cancer 65:e27408
Kurmasheva, Raushan T; Kurmashev, Dias; Reynolds, C Patrick et al. (2018) Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 65:

Showing the most recent 10 out of 6764 publications